Fusion protein · Inhibitor of Programmed cell death protein 1 (PDCD1) and Interleukin-21 receptor (IL21R) · developed by AMGEN
Latikafusp (AMG 256) is a fusion of an antibody against PD-1 with a mutein of interleukin-21. The antibody binds PD-1 on T-cells to inhibit its checkpoint signaling, while the IL-21 moiety binds the IL-21 receptor and activates cytokine signaling in PD-1-expressing cells. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
Advanced Solid Tumors
Updated Nov 1, 2026. Something wrong or missing? Report it on the AMGN page.
See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AMGN catalysts and pipeline →